Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Voyager Therapeutics, Inc. reported revenue of $40M, down 49.5% year over year. Operating margin was -326.6% and net margin -296.5%, on a free-cash-flow margin of -334.5% with capital expenditure at 6.4% of revenue. Every figure is computed directly from VYGR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $40M | -326.6% | -296.5% |
| FY2024 | $80M | -104.1% | -81.3% |
| FY2023 | $250M | 48.8% | 52.9% |
| FY2022 | $41M | -124.3% | -113.4% |
| FY2021 | $37M | -196.8% | -190.3% |
How does VYGR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.